Revealing How Interferon-Gamma Stops Tumor Cell Growth

At the UCLA Jonsson Comprehensive Cancer Center, scientists have uncovered a novel function for a protein known as extracellular signal-regulated kinase (ERK) within a pathway activated by interferon-gamma, capable of inducing cellular self-destruction.

Revealing How Interferon-Gamma Stops Tumor Cell Growth
Ameya Champhekar, first author of the study. Image Credit: University of California, Los Angeles

Their investigations revealed that interferon-gamma signaling triggered an excessive activation of ERK in human melanoma cell lines. When the ERK protein is hyperactive, it induces cellular stress, which, in turn, culminates in cell death, facilitated by specific proteins called DR5 and NOXA. The inhibition of ERK signaling prevented cell death in as many as 74% of these cell lines.

ERK signaling is always active at a low level in melanoma cells and is important for tumor cell survival. However, our data show that interferon-gamma causes overactivation of the ERK pathway, which triggers cell death. This establishes a new paradigm in the field that the overactivation of a pathway involved in oncogenic signaling is detrimental to cancer cells. This discovery sheds light on how interferon-gamma stops tumor cell growth and why it might not always work, helping us better understand how to overcome resistance.”

Ameya Champhekar, Study First Author and Adjunct Assistant Professor, Medicine, David Geffen School of Medicine, University of California, Los Angeles

Background

Interferon-gamma, a signaling molecule that stimulates the immune response, plays a role in triggering the immune system to identify and combat cancer cells. While its capacity to hinder tumor cell growth is established, the precise mechanisms behind this action remain incompletely elucidated. Comprehending the workings of interferon-gamma offers the prospect of therapeutically targeting this pathway and could provide a rationale for crafting innovative combination therapies.

Method

The research group employed a range of screening methodologies to decipher the impact of interferon-gamma on melanoma cells and its potential role in halting their proliferation. They conducted chemical genomics and comprehensive genome-focused CRISPR/Cas9 screens utilizing melanoma cell lines derived from patients to identify critical elements within the pathway responsible for interferon-gamma-induced growth inhibition.

Additionally, transcriptomic profiling was employed to ascertain which pathways leading to cell death were activated. To validate the involvement of these pathways in inducing cancer cell demise upon exposure to interferon-gamma, live imaging experiments were conducted in conjunction with apoptosis assays.

Impact

Despite the transformative impact of immunotherapy on cancer treatment, particularly for advanced cases, its efficacy remains limited to a small subset of patients. Interferon-gamma, a vital tool in the arsenal of T cells fighting tumor cells, has recently been found to permeate deeply into tumors, offering the potential for far-reaching growth-inhibitory effects on cancer cells.

Nevertheless, until this point, harnessing its capacity to impede tumor growth for clinical advantage has remained unclear. This newfound comprehension of the interferon-gamma growth inhibition pathway represents a crucial stride toward devising more effective approaches for targeting cancers that exhibit poor responsiveness to immunotherapy.

Source:
Journal reference:

Champhekar, A. S., et al. (2023). ERK mediates interferon gamma-induced melanoma cell death. Molecular Cancer. doi.org/10.1186/s12943-023-01868-x.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study Uncovers Cholesterol's Role in Membrane Structure and Function